Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Thyroid Neoplasms

• A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
• Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
• Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
• Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
• Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
• NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
• Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
• A Study of Avutometinib and Defactinib in People With Thyroid Cancer
• Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
• Pembrolizumab in High-risk Thyroid Cancer
• Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
• A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers
• Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
• DETERMINE Trial Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
• Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
• A Study of TY-1091 in Patients With Advanced Solid Tumors
• Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
• Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
• PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
• A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
• Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
• Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma
• Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
• Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases
• Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
• Treatment Using 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.
• Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry
• A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SY-5007 in Patients With Advanced Solid Tumors
• Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
• A Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
• Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy
• Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial
• Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.
• A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
• Individual Dosing of Levothyroxine After Thyroidectomy
• A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
• Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
• The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
• IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
• Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib
• A Randomized, Open-label Clinical Trial, Focus on the Safety and Efficacy of Anlotinib Hydrochloride in Combination With RAI in Patients With Local Advanced and Tyriod Cancer
• Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
• The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
• GFRα4 CAR T Cells in MTC Patients
• Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
• Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
• A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
• Energy Metabolism in Thyroidectomized Patients
• A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
• Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
• Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
• Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer
• Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
• A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
• Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
• A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
• Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition
• Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
• An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy
• Lidocaine And Neuromonitoring in Thyroid Surgery
• Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
• Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
• Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
• Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
• PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
• Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
• Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
• Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
• Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
• The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
• A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery
• Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
• Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
• Lenvatinib in Locally Advanced Invasive Thyroid Cancer
• Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
• Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
• Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
• Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
• 3-D Super Resolution Ultrasound Microvascular Imaging
• Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
• Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
• Bilateral Superficial Cervical Plexus Block in Thyroid/Parathyroid Surgery
• Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
• Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
• The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
• The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
• Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
• Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
• Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas
• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
• 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
• Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
• Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
• A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
• Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
• A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
• Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
• Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring
• Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
• Minimizing Narcotic Analgesics After Endocrine Surgery
• A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
• Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
• Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
• Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
• PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
• Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
• First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
• Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer
• IACS-010759 in Advanced Cancers
• Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
• Nivolumab Plus Ipilimumab in Thyroid Cancer
• Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC
• Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
• Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
• Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
• Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
• Selumetinib and Olaparib in Solid Tumors
• To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
• A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
• UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
• Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
• Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer
• Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
• Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
• Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
• Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
• Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
• Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
• The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients
• Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
• CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
• Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
• A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
• Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy
• PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
• Lenvatinib and Capecitabine in Patients With Advanced Malignancies
• Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
• Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
• Effect of Intravenous Magnesium on Postoperative Sore Throat After Thyroidectomy
• Study of Apatinib in Patients With Differentiated Thyroid Cancer
• Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
• Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer
• Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
• A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safe
• Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
• Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma
• A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
• Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
• Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
• Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
• Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
• A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
• Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
• Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
• 18F-FDOPA PET in Neuroendocrine Tumours
• Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
• Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
• Effect of Dexmedetomidine After Thyroidectomy
• Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
• Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
• 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
• An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
• Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
• Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
• Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
• A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
• An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
• Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy
• Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
• 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
• Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
• Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
• Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
• Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
• Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
• Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy
• CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
• 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
• Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
• Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
• A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
• Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery
• Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
• Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
• An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
• Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
• Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
• Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
• Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy
• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
• Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
• Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
• Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
• Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer
• Ponatinib for Advanced Medullary Thyroid Cancer
• Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
• A Multicenter Phase II Pilot Open Label
• Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
• Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
• Nintedanib(BIBF1120) in Thyroid Cancer
• An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
• The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
• Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
• A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours
• ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
• A Study of E7080 in Subjects With Advanced Thyroid Cancer
• Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
• Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
• Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
• Expanded Access of Cabozantinib in Medullary Thyroid Cancer
• Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
• Pioglitazone in Thyroid Cancers
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
• SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
• Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia
• Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
• Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
• Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
• To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
• Effect of Carum Carvi on Thyroid Hormones and TSH Level
• Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
• To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer
• Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
• Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
• Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer
• 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
• Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
• Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia
• Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Tre
• A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
• Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
• Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
• A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
• Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
• Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
• A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy
• Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
• A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
• Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients
• Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
• Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain
• Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
• A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
• Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
• Trial of LBH589 in Metastatic Thyroid Cancer
• Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
• RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-
• A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
• rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
• Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma
• Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
• Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
• Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
• A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
• Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
• Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
• Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
• Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
• A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
• An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
• Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
• Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
• Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer
• Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
• Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
• Thyroid Cancer and Sunitinib
• Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
• Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
• Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
• Study of XL281 in Adults With Solid Tumors
• Dental Safety Profile of High-Dose Radioiodine Therapy
• Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
• An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
• Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
• Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
• Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
• Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
• Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
• A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
• Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
• A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
• REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas
• Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
• Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
• Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
• Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
• Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
• Treatment for Patients With Metastatic Thyroid Cancer
• Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
• Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
• Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
• A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
• Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
• The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy
• Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
• Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
• Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
• Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
• Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
• Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
• Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
• Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
• Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
• Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
• Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
• Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
• Thalidomide in Treating Patients With Thyroid Cancer
• Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
• Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
• Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer
• Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
• Studies on Tumors of the Thyroid